Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor
Executive Summary
Pfizer's efforts to sustain growth for Lipitor in the face of forthcoming competition from generic versions of Merck's Zocor will focus on educating payers about atorvastatin's positive impact on overall healthcare costs relative to simvastatin, CEO Hank McKinnell said Jan. 4
You may also be interested in...
After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13
After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13
New Scripts May Be Juiced By Plan Switches Accompanying Part D – IMS
The number of new prescriptions reported since the implementation of Medicare Part D could be artificially inflated due to patients changing plans